ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1766

Role Of IL33 In The Inflammation Of Takayasu Arteritis

David Saadoun1, Marlène Garrido2, Julien Gaudric3, Cloé Comarmond4, Michele Rosenzwacjg5 and Patrice Cacoub6, 1Groupe Hospitalier Pitié Salpétrière, Service de Médecine Interne, DHU i2B, Paris, France, 2I3 laboratory, Pitié-Salpétrière, Paris, France, 3Department of Vascular surgery GHPS, Paris, France, 4Internal Medicine and Clinical Imunology, Referal Center for Autoimmune diseases, Internal Medicine and Clinical Imunology, Hôpital Pitié Salpétrière, Paris, France, 5Department of Immunology GHPS, Paris, France, 6Médecine Interne 2, Hopital Pitié-Salpétrière, Paris, France

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: cytokines, Inflammation, takayasu arteritis and vasculitis

  • Tweet
  • Email
  • Print
Session Information

Title: Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis II: Mechanisms that contribute to autoimmune inflammation

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Interleukin (IL)-33, a member of the IL-1 cytokine family, is a recently described novel activator of endothelial cells, which promotes adhesion molecules and proinflammatory cytokine expression in the endothelium and angiogenesis and vascular permeability. Unlike, the other IL-1 family members, IL-33 primarily induces T-helper (Th)2 immune responses and the polarisation of macrophages.

Objective: To analyse the role of IL-33 and its receptor ST2 in the pathogenesis of Takayasu arteritis (TA).

Methods:

Thirty three TA patients fulfilling the ACR criteria, with active disease (aTA) or inactive disease (iTA) and 10 age-matched controls (HD) were included. We performed quantitative measurement of IL-33, analysis of cell surface markers and cytokine production by flow cytometry and Luminex. Immunohistochemical analysis of inflamed aorta from patients with TA was performed.

Results:

Increased level of serum (mean ± SEM; 155 ± 69.5 vs 32.9 ± 19.6 pg/ml, respectively, p=0.040) and culture supernatants IL-33 (14.6± 3.3 vs 2.9 ±1.8 pg/ml, respectively, p=0.013) was observed in TA patients compared to HD. Level of IL-33 correlated with disease activity in TA patients (25.4± 6.5 in aTA vs 7.5 ±2.6 pg/ml in iTA, p=0.021) and with the NIH score (r2=0.3009, p=0.0009). IL-33 level dropped in active TA patients (n=10) that become inactive (20.1± 6.7 vs 4.2 ±1.2 pg/ml, p=0.031). IL-33 was mainly produced by eosinophils, basophils, and mast cells and in a lesser extent by macrophages and CD8+ T cells. ST2 (i.e. the IL-33 receptor) was mainly expressed by eosinophils and mast cells and much weaker by macrophages and neutrophils. IL-33 and ST2 were overexpressed in the inflamed arteries of TA patients and colocalized with endothelial cells and T cells, respectively. Stimulation of purified CD4+ T cells with IL-33 increased Th2 cells.

Conclusion:

These findings open new perspectives for the role of IL-33 in the pathogenesis of TA.


Disclosure:

D. Saadoun,
None;

M. Garrido,
None;

J. Gaudric,
None;

C. Comarmond,
None;

M. Rosenzwacjg,
None;

P. Cacoub,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/role-of-il33-in-the-inflammation-of-takayasu-arteritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology